4,5-annulated 1,2,4-triazolones

US10968216B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE
• The Broad Institute, Inc. · US
• President and Fellows of Harvard College · US
• The General Hospital Corporation · US

Inventors

• Stefan Nikolaus Gradl · Berlin, DE
• Duy Nguyen · Berlin, DE
• Knut Eis · Berlin, DE
• Judith Günther · Berlin, DE
• Timo Stellfeld · Berlin, DE
• Andreas Janzer · Berlin, DE
• Sven Christian · Berlin, DE
• Thomas Mueller · Langenfeld, DE
• Sherif El Sheikh · Neheim, DE
• Han Jie ZHOU · Foster City, US
• Changjia ZHAO · Beijing, CN
• David B. Sykes · Cambridge, US
• Steven James Ferrara · Cambridge, US
• Kery LIU · Beijing, CN
• Simon Anthony Herbert · Berlin, DE
• Claudia Merz · Berlin, DE
• Michael Niehues · Berlin, DE
• Carl Friedrich Nising · Leverkusen, DE
• Martina SCHÄFER · Berlin, DE
• Katja Zimmermann · Mülheim an der Ruhr, DE
• Jörg Knäblein · Berlin, DE
• Kai Thede · Berlin, DE
• Thomas Faupel · Berlin, DE

Key dates

• Filing date: Oct 25, 2017
• Grant date: Apr 6, 2021
• Expiry date: Oct 25, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.